NCT06795165

Brief Summary

A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Feb 2025

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 22, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 27, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

February 2, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 28, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2025

Completed
Last Updated

August 12, 2025

Status Verified

August 1, 2025

Enrollment Period

3 months

First QC Date

January 22, 2025

Last Update Submit

August 6, 2025

Conditions

Blepharitis

Keywords

blepharitisdemodex

Outcome Measures

Primary Outcomes (1)

  • Collarette count

    Collarette Count

    6 weels

Study Arms (3)

Active

ACTIVE COMPARATOR
Drug: Moxidectin 2 MG Oral Tablet

Active and Placebo

EXPERIMENTAL
Drug: Moxidectin 2 MG Oral TabletDrug: Placebo

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Moxidectin 2 MG Oral TabletDRUG

active medication

ActiveActive and Placebo
PlaceboDRUG

placebo pills

Active and PlaceboPlacebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Active blepharitis with collarettes

You may not qualify if:

  • Other clinically significant eye disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye Research Foundation, Inc.

Newport Beach, California, 92663, United States

Location

MeSH Terms

Conditions

Blepharitis

Interventions

moxidectinTablets

Condition Hierarchy (Ancestors)

Eyelid DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Dosage FormsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2025

First Posted

January 27, 2025

Study Start

February 2, 2025

Primary Completion

April 28, 2025

Study Completion

June 15, 2025

Last Updated

August 12, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

US(1)